Literature DB >> 28050363

First Line Anti-TB Drug Resistance in an Urban Area of Odisha, India.

Dasarathi Das1, Prakasini Satapathy2, Biswanath Murmu3.   

Abstract

INTRODUCTION: Drug resistance is a major cause for increasing the global burden of Tuberculosis (TB). However in countries with larger geographical areas and different climatic conditions like India the prevalence of drug resistance varies from place to place. Information on anti-TB drug resistance patterns particularly among newly diagnosed cases is crucial for planning an effective TB control program. AIM: To determine the prevalence of resistance against first line anti-TB drugs and Multi Drug Resistance (MDR) in Mycobacterium tuberculosis isolates.
MATERIALS AND METHODS: The prospective study was carried out in National Reference Laboratory (NRL) of Regional Medical Research Centre (RMRC), Bhubaneswar. During this period from January to September 2014, sputum specimens were collected from 850 suspected pulmonary TB patients attending Designated Microscopy Center (DMC) of Capital Hospital, Bhubaneswar, Odisha. Sputum specimens were subjected to Acid Fast Bacilli (AFB) smear microscopy and further processed for isolation on solid Lowenstein Jensen (LJ) medium. Drug Susceptibility Testing (DST) on isolates with first line anti-TB drugs was performed as per Revised National Tuberculosis Control Programe (RNTCP) guidelines.
RESULTS: Out of all the 850 suspected pulmonary TB patients subjected to AFB microscopy and solid LJ culture, isolation of Mycobacterium tuberculosis was successful only in 161 (117 new and 44 previously treated) pulmonary TB patients. On DST by the RNTCP approved proportion method, prevalence of MDR- TB among 0.85% new and 4.54% previously treated cases was observed. Prevalence of mono resistance to streptomycin, isoniazid, rifampicin and ethambutol observed among new and previously treated cases were 3.41%, 2.56%, 0, 0.85% and 2.27%, 13.6%, 2.27%, 0 respectively. Only one patient from each category showed resistance to both streptomycin and isoniazid in previously treated as well as in new case.
CONCLUSION: The study reports an unchanged low level of MDR-TB prevalence among new cases in an urban area of Odisha over a decade. This could be due to the success of Directly Observed Treatment Short-course (DOTS) in effective treatment of drug-susceptible TB in the state and non-transmission from primary Drug Resistance (DR) TB cases.

Entities:  

Keywords:  Acid fast bacilli; Isoniazid; Multi-drug resistant

Year:  2016        PMID: 28050363      PMCID: PMC5198316          DOI: 10.7860/JCDR/2016/20289.8846

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  9 in total

1.  Low levels of anti TB drug resistance in Rayagada district of Odisha, India.

Authors:  D Das; B Dwibedi; S K Kar
Journal:  Int J Mycobacteriol       Date:  2013-11-27

2.  Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis.

Authors:  Mohamed Abdel Aziz; Abigail Wright; Adalbert Laszlo; Aimé De Muynck; Françoise Portaels; Armand Van Deun; Charles Wells; Paul Nunn; Leopold Blanc; Mario Raviglione
Journal:  Lancet       Date:  2006-12-16       Impact factor: 79.321

3.  Multidrug-resistant and extensively drug resistant tuberculosis in Kashmir, India.

Authors:  Bikram Singh Datta; Ghulam Hassan; Syed Manzoor Kadri; Waseem Qureshi; Mustadiq Ahmad Kamili; Hardeep Singh; Ahmad Manzoor; Mushtaq Ahmad Wani; Natasha Thakur
Journal:  J Infect Dev Ctries       Date:  2009-11-21       Impact factor: 0.968

4.  High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India.

Authors:  Desiree T B D'souza; Nerges F Mistry; Tina S Vira; Yatin Dholakia; Sven Hoffner; Geoffrey Pasvol; Mark Nicol; Robert J Wilkinson
Journal:  BMC Public Health       Date:  2009-06-29       Impact factor: 3.295

5.  Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.

Authors:  R Ramachandran; S Nalini; V Chandrasekar; P V Dave; A S Sanghvi; F Wares; C N Paramasivan; P R Narayanan; S Sahu; M Parmar; S Chadha; P Dewan; L S Chauhan
Journal:  Int J Tuberc Lung Dis       Date:  2009-09       Impact factor: 2.373

6.  Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients.

Authors:  Surendra K Sharma; Sanjeev Kumar; P K Saha; Ninoo George; S K Arora; Deepak Gupta; Urvashi Singh; M Hanif; R P Vashisht
Journal:  Indian J Med Res       Date:  2011-03       Impact factor: 2.375

7.  Situation of drug resistant tuberculosis in Saharia tribe of central India.

Authors:  J Bhat; V G Rao; R Yadav; M Muniyandi; R Sharma; C Karfarma; C Luke
Journal:  Indian J Med Res       Date:  2015-05       Impact factor: 2.375

8.  Disease control implications of India's changing multi-drug resistant tuberculosis epidemic.

Authors:  Sze-Chuan Suen; Eran Bendavid; Jeremy D Goldhaber-Fiebert
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

9.  First and second line drug resistance among treatment naïve pulmonary tuberculosis patients in a district under Revised National Tuberculosis Control Programme (RNTCP) in New Delhi.

Authors:  Vithal Prasad Myneedu; Ritu Singhal; Khalid Umer Khayyam; Prem Prakash Sharma; Manpreet Bhalla; Digamber Behera; Rohit Sarin
Journal:  J Epidemiol Glob Health       Date:  2015-05-02
  9 in total
  2 in total

1.  Evaluation of the frequency of resistance to 2 drugs (Isoniazid and Rifampin) by molecular investigation and it's risk factors in new cases of smear positive pulmonary tuberculosis in health centers under the cover of Jundishapur University of Medical Sciences in 2017.

Authors:  Shokrollah Salmanzadeh; Masoumeh Karamian; Seyed Mohammad Alavi; Roohangiz Nashibi
Journal:  J Family Med Prim Care       Date:  2020-04-30

2.  Differential yield of universal versus selective drug susceptibility testing of patients with tuberculosis in high-burden countries: a systematic review and meta-analysis.

Authors:  Anita Svadzian; Giorgia Sulis; Genevieve Gore; Madhukar Pai; Claudia M Denkinger
Journal:  BMJ Glob Health       Date:  2020-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.